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We aimed to determine the role of HPV in the pathogenesis and outcome of oropharyngeal squamous cell carcinoma (OSCC)
in lifelong nonsmoking and nondrinking patients. A case-case analysis was performed to compare the presence of HPV-DNA
in tumor cells of 16 nonsmoking and nondrinking with 16 matched smoking and drinking patients (matching criteria: age
at incidence, gender, tumor sublocation, tumor stage). HPV was detected using 2 PCR tests, FISH analysis, and p16INK4A
immunostaining. Nonsmoking and nondrinking patients had more HPV-positive tumors than smoking and drinking patients
(n = 12; 75% versus n = 2; 13%; P < 0.001). All HPV-positive tumors showed p16INK4A overexpression, and 1HPV-negative tumor
had p16INK4A overexpression, (P < 0.001). Overall survival and disease-specific survival were higher for HPV-positive compared
to HPV-negative cases (P = 0.027, P = 0.039, resp.). In conclusion, HPV is strongly associated with OSCC of nonsmoking
and nondrinking patients. Specific diagnostic and therapeutic actions should be considered for these patients to achieve a better
prognosis.
1. Introduction
The most important risk factors for developing head and
neck squamous cell carcinoma in the Western countries are
consumption of tobacco and alcohol [1]. However, there is a
small population of nonsmoking and nondrinking patients
with head and neck squamous cell carcinoma, so other
risk factors may be important [2]. Substantial evidence has
shown that oncogenic human papillomavirus (HPV), which
is the primary cause of uterine cervical cancer, is etiologically
involved in the development of head and neck squamous cell
carcinoma [3–10].
It is estimated that up to 15–20% of all head and neck
squamous cell carcinomas are associated with high-risk HPV
infection [3–10]. This prevalence varies broadly, depending
on the sublocation of the tumor, the studied population,
the detection method, and the type of specimen used [4–
10]. The highest rates of HPV-DNA (up to 70%) have been
found in oropharynx squamous cell carcinomas (OSCCs),
especially the tonsils. HPV type 16 has been detected in 90–
95% of HPV-related OSCC, HPV-18 in some cases, and HPV
type 31, -33, and -35 in considerably less cases [7, 9–13].
In the pathogenesis of HPV-related cancer, integration
of the viral genome into the cellular DNA and, as a result,
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upregulation of the viral oncoproteins E6 and E7 seem to be
crucial events. These oncoproteins subsequently cause dys-
function of amongst others tumor suppressor proteins, p53
and pRb, respectively, leading to cell proliferation, impaired
apoptosis, and ultimately chromosome instability [14].
Immunohistochemical detection of p16INK4A overexpres-
sion, a product of tumor suppressor gene CDKN2A, has
been associated with HPV-related head and neck squamous
cell carcinoma and in some studies used as a surrogate
biomarker for HPV detection [5, 15, 16]. Recent studies
have characterized a subset of HPV-related OSCC in which
p16INK4A overexpression predicts the presence of oncogenic
HPV infection and identifies those with a better prognosis
[17, 18]. Moreover, deletion of the CDKN2A locus together
with functional inactivation of the tumor suppressor protein
p16INK4A have been detected in head and neck squamous
cell carcinoma without a relationship with HPV infection
[19, 20].
HPV-positive head and neck squamous cell carcinomas
are predominantly poorly diﬀerentiated and show a char-
acteristic basaloid morphology in comparison with HPV-
negative tumors [4, 6]. Furthermore, patients with HPV-
positive tumors are less likely to consume large amounts
of tobacco and alcohol [9, 15, 21, 22] and seem to have a
better response to radiotherapy and a favorable survival rate
[4, 11, 18, 23, 24]. So there are signs that these tumors form a
separate entity within the heterogeneous group of head and
neck squamous cell carcinomas.
The correct determination of HPV’s involvement in the
pathogenesis and prognosis of OSCC is dependent on several
patient- and tumor-related cofactors, such as tobacco and
alcohol use, TNM stage, and treatment modality. Although
most investigators have found a trend between HPV and
lesser amount of tobacco and alcohol use, the definitions of
the used amounts are not always clear. Furthermore, to date,
no matched analysis with smoking and drinking patients has
been performed. In addition, previous studies have often
used only one assay to determine the biological association
of HPV infection with tumorigenesis.
In this study, we aimed to determine the role of HPV
in carcinogenesis and disease outcome for nonsmoking and
nondrinking patients with OSCC. Therefore, we performed
a case-case study of a well-defined population of 16 non-
smoking and nondrinking and 16 matched, smoking and
drinking patients with OSCC for the presence of HPV DNA
and overexpression of biomarker p16INK4A. The presence
of HPV DNA was analysed using three diﬀerent methods,
that is, fluorescence in situ hybridization (FISH) and two
polymerase-chain-reaction- (PCR-) based assays (Amplicor
and Linear Array HPV detection kits).
2. Material and Methods
Patients were selected from a database at the University
Medical Center Utrecht, in which all patients with newly
diagnosed head and neck squamous cell carcinoma are
prospectively registered. Between 1980 and 2004, 4607
patients were entered in the database. This database contains
information on patient characteristics, risk factors, tumor
classification, treatment modalities, and follow-up data
including number of recurrences and subsequent primary
tumors. Patients were classified as nonsmoking and non-
drinking (n = 198), when they had no history of smoking
tobacco and alcohol consumption. Patients were classified
as smoking and drinking (n = 2181), when they actively
smoked tobacco and consumed alcohol. Former smokers
or drinkers were not included. All patients were treated
according to institutional protocols, and final decision was
made in consultation with the patient. Follow-up time (in
months) was considered from the date of diagnosis (i.e., first
proven biopsy) to the date of death or date of last followup
(January 1, 2009). Seventeen nonsmoking and nondrinking
patients with a primary head and neck squamous cell
carcinoma located in the oropharynx (ICD codes 141.0,
145.3, 145.4, 146.0, 146.1, 146.2, 146.3, and 146.6) were
found in the database of which 16 were selected because
of absence of tumor tissue in 1 case. These patients were
matched with smoking and drinking patients on gender, age
(±5 years), sublocation of tumor, and tumor stage. A case-
case analysis was performed to compare the prevalence of
HPV DNA and overexpression of p16INK4A in both groups.
2.1. Tissue Specimens. 32 formalin-fixed, paraﬃn-embedded
(FFPE) tumor tissue blocks from either biopsy or surgical
resection specimens were obtained. Two experienced head
and neck pathologists (JAK, PS) examined H&E-stained
slides to select the areas in which tumor cells were present
and evaluated themorphological appearances. Both patholo-
gists were blinded to the smoking and drinking status. Tumor
grade was recorded as well, moderate, or poor according
to the criteria of the World Health Organization [25]. In
addition, tumors were assessed for the absence or presence
of hyperkeratosis, vasoinvasive and perineural growth, and
typical basaloid features, that is, small, dark cells with scant
cytoplasm, hyperchromatic nuclei, marked mitotic activity, a
predominant lobular pattern of growth, and the absence of
prominent keratinisation [26].
2.2. HPV Analysis
2.2.1. DNA Isolation and PCR Analysis. For DNA extraction
tumor, areas from FFPE slides were isolated by microdis-
section. After deparaﬃnization, the tissue fragments were
digested in 150 μL 50mM Tris/HCL (pH 8.0) 0,5% (v/v)
Tween-20 with proteinase K (final concentration 2mg/mL).
After 1 hour incubation at 56◦C, the lysates were boiled to
inactivate the proteinase K and subsequently centrifuged.
Supernatants were transferred into clean eppendorf tubes
and directly used for PCR. PCR was performed using the
Amplicor HPV Test kit (Amplicor HPV Amplification kit:
03610799 190, Amplicor HPV Detection kit: 03610799 190,
Amplicor HPV Controls Kit: 03610756 190; Roche, Basel, Sz)
as well as the Linear Array HPV Genotyping Test (Linear
Array HPV Genotyping Kit: 03378179 190, Linear Array
HPV Detection Kit: 208693; Roche). Both tests were carried
out according to the manufacturer’s recommended protocol
including positive and negative controls. The Amplicor test
is a qualitative in vitro test which uses amplification of target
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DNA by PCR and nucleic acid hybridization for the detection
of high-risk HPV DNA genotypes (i.e., HPV types 16, 18, 31,
33, 35, 39, 45, 52, 56, 58, 59, 66, and 68). It uses primers
to define a sequence of nucleotides within the L1 region
of the HPV genome that is 150 base-pair (bp) long. This
test also features a concurrent isolation and amplification
of the human β-globin gene to assess DNA integrity for
each tested specimen. The Linear Array test uses the same
detection technique; however, it targets an HPV genome
sequence of 450 bp and is able to detect high-risk (same types
asmentioned above) as well as low-risk HPV-DNA (i.e., HPV
types 6, 11, 40, 42, 43, and 44).
2.2.2. FISH. FISH was performed on 4 μm thick tissue
sections as described previously [5, 15]. Briefly, sections were
deparaﬃnized, pretreated with 85% formic acid/0.3% H2O2,
1M NaSCN, and 4mg/mL pepsin in 0.02MHcl, postfixed
in 1% formaldehyde in PBS, dehydrated in an ethanol series,
and hybridized with a digoxigenin-labeled HPV 16-specific
probe (PanPath, Amsterdam, The Netherlands) according
to the manufacturer’s instructions. After hybridization, the
preparations were washed stringently in 50% formamide,
2×SSC, pH 7.0 at 42◦C (2 times 5min). The probes were
detected by application of mouse antidigoxin (Sigma, St.
Louis, MO), peroxidase-conjugated rabbit antimouse IgG,
and peroxidase-conjugated swine antirabbit IgG (both Dako;
Glostrup, Dk) and visualized by a peroxidase reaction using
rhodamine-labeled tyramide. Preparations were mounted in
Vectashield (Vector Laboratories, Burlingame, Calif, USA)
containing 4,6-diamidino-2-phenyl indole (DAPI; Sigma:
0.2 ug/mL). Microscope images were recorded with the
Metasystems Image Pro System (black and white CCD
camera; Sandhausen, Germany) mounted on top of a Leica
DM-RE fluorescence microscope equipped with DAPI and
rhodamine filters. Evaluation of nuclear hybridization signals
was performed by two investigators (FF and EJMS) according
to the previously described criteria [15]: punctate and/or
diﬀuse signals throughout the nucleus indicating integrated
and episomal HPV DNA, respectively, and granular FISH
pattern if >1 nuclear signals, varying significantly in size
and intensity, were observed. Control hybridizations were
performed as described previously [15].
2.2.3. Immunohistochemical Detection of P16INK4A. 4 μm
thick tissue sections were deparaﬃnized with xylene and
rehydrated by serial ethanol dilutions. Endogenous perox-
idase activity was blocked by incubation for 30 minutes
with 0.3% (v/v) H2O2 in methanol followed by antigen
retrieval by boiling in 0.01M sodium citrate buﬀer pH
6 for 15 minutes in a microwave oven. Slides were then
incubated with a p16INK4A-specific primary mouse mono-
clonal antibody (Neomarkers, Fremont, USA) and diluted
1 : 160 for one hour at room temperature followed by a
secondary visualisation reagent for 45 minutes (Powervi-
sion Goat-anti-Mouse/Rabbit/Rat labelled with horseradish
peroxidase, ImmunoLogic, ImmunoVision Technologies,
Brisbane, USA). After each incubation step, slides were
washed in phosphate-buﬀered saline containing 3% (w/v)
BSA. Peroxidase activity was visualized by incubation with
diaminobenzidine/H2O2, and cell nuclei were counterstained
with hematoxylin. All p16INK4A-positive cases were assessed
for nuclear and/or cytoplasmic staining pattern. The staining
patterns were scored semiquantitatively for the percentage of
p16INK4A-positive tumor cells. The sections were graded as
positive (+) when at least 75% of the tumor cells showed
p16INK4A positivity and as negative (−) when no staining
was visible. Only one case (Table 2) showed 25% p16INK4A-
positive tumor cells and was considered as ±.
2.2.4. Statistics. The association between HPV status and
other variables was tested using Chi-square and Fisher’s exact
test. Disease-specific survival (i.e., death due to primary
tumor, tumor recurrence, or subsequent primary tumor)
and overall survival (i.e., mortality due to all causes)
were determined for HPV-positive and HPV-negative cases,
nonsmoking and nondrinking and smoking and drinking
groups, and for cases with and without p16INK4A overexpres-
sion using a univariate approach (i.e., Kaplan-Meier)method
as patients were matched on possible confounding factors.
Estimated survival curves were compared using log-rank test.
A P value ≤ 0.05 was considered statistically significant.
3. Results
Sixteen nonsmoking and nondrinking patients with OSCC
were matched with 16 smoking and drinking patients
according to the above-mentioned criteria. The smoking and
drinking patients used the following amounts of tobacco and
alcohol at the time of diagnosis: 2–4 units of alcohol/day
(n = 10), 5–9 units of alcohol/day (n = 4), and >9 units
of alcohol/day (n = 2); ≤20 cigarettes/day (n = 5) and >20
cigarettes/day (n = 11). For 2 nonsmoking and nondrinking
patients, the best possible match was disease stage IVA
instead of III. The incidence dates ranged from 1980 to 2005.
Table 1 summarizes the basic clinical characteristics of all
cases.
HPV status for all cases was determined using two PCR-
based test kits and FISH analysis (Table 2). The Amplicor
PCR test showed 12 HPV-positive and 15 HPV-negative
cases and was in 5 cases inconclusive due to negative β-
globin gene results. The Linear Array PCR test showed 7
HPV-positive and 19 HPV-negative cases, and 6 cases that
were inconclusive due to negative β-globin gene results.
The FISH analysis revealed 12 HPV 16-positive cases of
which 1 with a very low signal intensity (4B), and 19
cases without a detectable signal and 1 case which was
inconclusive due to insuﬃcient tissue material. Eight of the
FISH-positive cases showed punctate signals in the tumor
cell nuclei indicating integrated HPV DNA, and 4 showed
granular nuclear staining. Based on these outcomes (see also
discussion), we determined the HPV status as follows: 12 of
16 nonsmoking and nondrinking cases (75%) had a positive
HPV status versus 2 of 16 smoking and drinking controls
(12.5%, P < 0.001, Tables 2 and 3).
Immunohistochemical analysis for biomarker p16INK4A
was detected as shown in Tables 2 and 3. p16INK4A overex-
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Figure 1: (a) Overall survival for HPV-positive compared to HPV-negative cases. (b) Disease-specific survival for HPV-positive compared
to HPV-negative cases.
pression (at least 75% of cells with positive staining) was
found in 14 cases (44%), in 1 case (1B) 25% of cells stained
positive (3%) and 17 cases (53%) were negative. All positive
cases had strong nuclear as well as cytoplasmic staining
except case 16B which showed predominantly cytoplasmatic
staining. All HPV-positive cases had p16INK4Aoverexpression,
whereas 17 of 18 HPV-negative cases had no detectable
p16INK4A (P < 0.001, Table 3).
The associations between HPV status and tumor subsite,
T- or N-classification, tumor stage, year of initial diagnosis,
treatment, and vasoinvasive and perineural growth were
not significant (Table 3). In contrast, HPV-positive tumors
showed significantly less often keratinisation (P = 0.025) and
more often basaloid features (P = 0.039, Table 3). Tumor
recurrence was found in 3 HPV-positive (2 locoregional
and 1 distant) and 3 HPV-negative cases (all locoregional)
and in 2 nonsmoking and nondrinking and 4 smoking
and drinking patients. Second primary tumor was found
in 1 HPV-positive (in the oral cavity) and 4 HPV-negative
cases (1 oral cavity, 3 oropharynx, and 1 lung) and in 1
nonsmoking and nondrinking patient and 5 smoking and
drinking patients (Table 3, no significant correlations).
3.1. Survival Data. Follow-up time ranged from 5.9 to 182.1
months.Median follow-up time was 61.1months. The 5-year
overall and disease-specific survival for all cases was 53% and
64%, respectively. Cause of death in 20 deceased patients was
as follows: due to primary tumor (n = 4; 1 nonsmoking and
nondrinking, 3 smoking and drinking), other causes (n = 7;
4 nonsmoking and nondrinking, 3 smoking and drinking) of
which 5 cardial and 2 pulmonary disease, recurrent disease
(n = 6; 2 nonsmoking and nondrinking, 4 smoking and
drinking), and second primary tumor (n = 3 smoking and
drinking). For HPV-positive and HPV-negative cases, the 5-
year overall survival was 71% and 42%, and 5-year disease-
specific survival was 76% and 57%, respectively. Overall
and disease-specific survival were both significantly higher
for HPV-positive compared to HPV-negative cases (P =
Table 1: Basic characteristics of all cases.
Nonsmoking and nondrinking
Smoking and
drinking
n n
Gender
Male 3 3
Female 13 13
Age at tumor incidence (years)
Mean 64.8 63.0
Range 45–83 50–78
Tumor stage
II 3 3
III 6 4∗
IVA 7 9∗
Year of initial diagnosis
1982–1986 2 1
1987–1991 2 3
1992–1996 6 5
1997–2001 2 5
2002–2006 4 2
Tumor location (ICD-code)
Base of tongue (141.0) 6 6
Tonsil (146.0) 5 5
Tonsillar fossa (146.1) 3 3
Vallecula (146.3) 2 2
∗
Best possible match for 2 cases was stage IVA instead of III.
0.027, P = 0.039, resp., Figure 1), for nonsmoking and
nondrinking patients compared to the smoking and drinking
counterparts (P = 0.037, P = 0.013, resp.) and for cases
with p16INK4A overexpression compared to those without
detectable p16INK4A overexpression (P = 0.028, P = 0.030,
resp.).
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Table 2: HPV and p16INK4A results of all cases.
Case-case
p16INK4A
overexpression
HPV
Final HPV
outcome
PCR PCR
(Amplicor) (Linear Array) FISH
1A∗ + Present HPV-33/52,33,35,58 Absent§ Positive
1B† ± Present Absent Absent Positive
2A + Present Absent Present Positive
2B + Present HPV-16 Present Positive
3A + Present HPV-16 Present Positive
3B − Absent Absent Absent Negative
4A + Present HPV-16 Present Positive
4B − Absent Absent Present|| Negative
5A + Present Absent Present Positive
5B − Absent Absent Absent Negative
6A + Present HPV-16 Present Positive
6B − Absent Absent Absent Negative
7A + Present HPV-16 Present Positive
7B − Absent Absent Absent Negative
8A + Present HPV-16 Present Positive
8B − Absent Absent Absent Negative
9A + NO‡ NO‡ Present Positive
9B − Absent Absent Absent Negative
10A + Present NO‡ NO‡ Positive
10B − Absent Absent Absent Negative
11A + Present NO‡ Present Positive
11B − Absent Absent Absent Negative
12A + NO‡ NO‡ Present Positive
12B − NO‡ NO‡ Absent Negative
13A − Absent Absent Absent Negative
13B − Absent Absent Absent Negative
14A − Absent Absent Absent Negative
14B − Absent Absent Absent Negative
15A − Absent Absent Absent Negative
15B − Absent Absent Absent Negative
16A − NO‡ NO‡ Absent Negative
16B + NO‡ Absent Absent Negative
∗
A: nonsmoking and nondrinking.
†B: smoking and drinking.
‡Not obtained (for PCR tests, for example, due to a negative β-globin PCR).
§HPV-16-specific FISH probe.
||poor signal.
4. Discussion
To date, this study is the first that analyses the role of
HPV in the pathogenesis and clinical behavior of OSCC
in nonsmoking and nondrinking patients in comparison
with matched smoking and drinking patients. HPV was
strongly associated with OSCC in the absence of tobacco
and alcohol use. HPV was found in 86% of the nonsmoking
and nondrinking patients compared to 22% of the smoking
and drinking patients. Our results are consistent with other
studies although they mostly have shown this association
separately in a group of nonsmokers or in a group of
nondrinkers. Lindel et al. found HPV in 62 percent of
nonsmokers and 38 percent of nondrinkers with oropharyn-
geal tumors [9]. Tachezy et al. demonstrated HPV-positive
oropharynx and oral cavity tumors in all nonsmokers and
69% of nondrinkers, and in a recent study, nonsmoking
and nondrinking patients with OSCC were reported to be
6.1 times more likely to be infected with high-risk HPV
[22, 27]. One could hypothesize that smoking and drinking
are independent risk factors and that the eﬀect of HPV is
enriched in the absence of these risk factors [28]. Increasing
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Table 3: Characteristics of all cases according to HPV status.
HPV n (%)
Positive Negative
Variable (n = 14) (n = 18) P value
Tobacco and Alcohol <0.001
Nonsmoking and nondrinking 12 (86) 4 (22)
Smoking and drinking 2 (14) 14 (78)
p16INK4A overexpression <0.001
+ 13 (93) 1 (6)
− 0 17 (94)
± 1 (7) 0
Tumor location (ICD-code) NS∗
Base of tongue (141.0) 4 (29) 8 (45)
Tonsil (146.0) 4 (29) 6 (33)
Tonsillar fossa (146.1) 4 (29) 2 (11)
Vallecula (146.3) 2 (15) 2 (11)
Tumor NS
T1 3 (21) 1 (6)
T2 6 (43) 7 (39)
T3 3 (21) 6 (33)
T4 2 (15) 4 (22)
NS
T1-T2 9 (65) 8 (45)
T3-T4 5 (35) 10 (55)
Nodal involvement NS
N0 4 (29) 7 (39)
N1 3 (21) 4 (22)
N2 7 (50) 7 (39)
Stage NS
II 2 (15) 4 (22)
III 5 (35) 5 (28)
IVA 7 (50) 9 (50)
Year of initial diagnosis NS
1982–1986 1 (7) 2 (11)
1987–1991 2 (15) 3 (17)
1992–1996 6 (43) 5 (28)
1997–2001 2 (15) 5 (28)
2002–2006 3 (21) 3 (17)
Treatment modality NS
Radiotherapy 6 (43) 6 (33)
Chemotherapy + radiotherapy 2 (15) 0
Surgery + radiotherapy 5 (35) 9 (50)
Surgery 0 2 (11)
Chemotherapy 0 1 (6)
Supportive 1 (7) 0
Tumor grade NS
Moderate 7 (50) 4 (22)
Poor 7 (50) 14 (78)
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Table 3: Continued.
HPV n (%)
Positive Negative
Variable (n = 14) (n = 18) P value
Perineural growth NS
Yes 4 (29) 2 (11)
No 10 (71) 16 (89)
Vasoinvasive growth NS
Yes 3 (21) 1 (6)
No 11 (79) 17 (94)
Keratinization 0.025
Yes 3 (21) 11 (61)
No 11 (79) 7 (39)
Basaloid features 0.039
Yes 9 (65) 5 (28)
No 5 (35) 13 (78)
Tumor recurrence NS
Yes 3 (21) 3 (17)
No 11 (79) 15 (83)
Second primary tumor NS
Yes 1 (7) 4 (22)
No 13 (93) 14 (78)
∗
Nonsignificant.
evidence shows a particular risk factor profile for HPV-
related head and neck squamous cell carcinoma with not
only less consumption of tobacco and alcohol but also a
diﬀerent sexual behavior and higher use of marijuana in
mostly younger patients (<55 years [28]) compared to non-
HPV-associated head and neck squamous cell carcinoma
[21, 29, 30]. We do not have patient data regarding sexual
behavior and use of drugs in our studied population.
Additional characteristics of our studied HPV-positive
tumors included the presence of basaloid features and lack of
keratinisation which has been reported by previous studies
[4, 6]. Likewise in this study as well as numerous other
studies, HPV-related tumors proved to be associated with not
only a better overall survival but also a better disease-specific
survival [4, 9, 16, 23, 24]. The underlying mechanism for this
prognostic eﬀect of HPV is unclear. Although only one HPV-
positive case had a second primary tumor compared to three
HPV-negative cases, this diﬀerence was not significant. Also
no correlation was found between recurrent disease or diﬀer-
ent treatment modalities and HPV positivity. Nevertheless,
a better response on treatment like an increased sensitivity
for radiotherapy possibly due to remaining amounts of
p53 function in HPV-associated tumors might also explain
the favorable prognosis. Worden et al. found induction
chemotherapy followed by chemoradiotherapy to be an
eﬀective treatment in especially HPV-positive OSCC [31].
So it seems important to recognize patients with HPV-
related head and neck squamous cell carcinoma to customize
therapeutic decisions. Moreover, combination of HPV with
recently identified prognostic indicators such as loss of
chromosome 16q and the presence of p21CIP1/WAF1or nuclear
survivin expression holds further promise to select patients
for this purpose [19].
We also found better overall and disease-specific survival
for nonsmoking and nondrinking cases and those with
p16INK4A overexpression compared to their counterparts. We
consider these results to be related to HPV positivity. In
another recent study by our studygroup regarding disease
outcome for all head and neck squamous cell carcinoma in
our center, we found no diﬀerence in survival between those
who smoke and drank and those who did not [32].
Some controversy exists concerning the most reliable way
to determine biologically relevant HPV infection in FFPE
tissue. Therefore, it has been proposed to use at least more
than one method to identify a firm association of the virus
with the tumor cells. Most studies agree upon the use of the
surrogate marker p16INK4A followed by a HPV-specific test,
such as HPV DNA PCR [16, 18], HPV E6 RT-PCR [17], or
HPV FISH [15, 33]. We used four methods to detect the
HPV status, that is, p16INK4A immunostaining, PCR using
two diﬀerent test kits, and FISH analysis, which strongly
correlated with each other. In 4 cases (9A, 12A, 12B, and
16A), the β-globin gene could not be amplified by both PCR
tests; hence, the FISH data were used to determine the HPV
status, which corresponded with the presence of p16INK4A
overexpression in case of HPV positivity. Nevertheless, also
some discrepancies were found between the diﬀerent tests
used. In cases 5A and 2A, the Amplicor test was positive for
HPV, whereas the Linear Array test was negative, probably
due to the large fragments that need to be amplified in the
latter assay. As a consequence, the Amplicor and the FISH
results were used to proof HPV positivity for these cases.
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In case 1A, PCR revealed the presence of HPV DNA of
types 33/52, 33, 35, and 58 with corresponding p16INK4A
overexpression, which explains the negative outcome of the
HPV type 16-specific FISH analysis. Only in cases 1B and
4B, FISH analysis did not correlate with PCR and p16INK4A
immunostaining, and in these cases, we decided to consider a
positive p16INK4A and PCR status as signs for HPV positivity.
However, the opposite may also be true as one considers the
very high sensitivity of HPV DNA PCR, which may lead to
false-positive results [34], as well as the fact that p16INK4A can
be overexpressed without the presence of HPV, for example,
case 16B and a study by Hafkamp et al. [15]. On the other
hand, the p16INK4A staining pattern in case 16B was purely
cytoplasmic in contrast to the other p16INK4A-positive cases
in which cytoplasmic and nuclear pattern was seen. This may
point to other reasons than HPV for upregulation of this
biomarker. Furthermore, the results as mentioned in Table 3
and survival curves would not be aﬀected by opposite results
of cases 1B and 4B.
We conclude that HPV is strongly associated with
oropharyngeal tumors, especially in lifelong nonsmokers
and nondrinkers. With better and more valid detection
techniques, it is likely that these patients will be recognized as
a specific entity within the heterogeneous group of head and
neck cancer. Diagnostic and therapeutic actions will then be
more focussed on this distinct group and may lead to better
prognosis.
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